Eran CPA - Collplant Biotechnologies Deputy CFO
| CLGN Stock | USD 4.48 0.23 5.41% |
Insider
Eran CPA is Deputy CFO of Collplant Biotechnologies
| Age | 56 |
| Address | Weizmann Science Park, Rehovot, Israel, 7670104 |
| Phone | 972 73 232 5600 |
| Web | https://www.collplant.com |
Collplant Biotechnologies Management Efficiency
The company has return on total asset (ROA) of (0.3377) % which means that it has lost $0.3377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6155) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Collplant Biotechnologies' Other Current Assets are very stable compared to the past year. As of the 30th of November 2024, Intangible Assets is likely to grow to about 265.7 K, while Total Assets are likely to drop about 18.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Ikena Oncology | 59 | |
| Joseph Bolen | PureTech Health PLC | 70 | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| Cecilia Geuijen | Merus BV | N/A | |
| Conor Richardson | Shattuck Labs | N/A | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Michele MBA | Prelude Therapeutics | N/A | |
| David Elmaleh | PureTech Health PLC | 76 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Elias Papadimas | Exicure | 48 | |
| Sushil Patel | Replimune Group | 53 | |
| FACC Facc | NewAmsterdam Pharma | 65 | |
| Cornelis Kruif | Merus BV | 59 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Peter Rhode | HCW Biologics | 66 | |
| Dr MBA | MediciNova | 59 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Abhinav Shukla | Shattuck Labs | ||
| Jonathan Siegal | Vericel Corp Ord | N/A | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.34 |
Collplant Biotechnologies Leadership Team
Elected by the shareholders, the Collplant Biotechnologies' board of directors comprises two types of representatives: Collplant Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Collplant. The board's role is to monitor Collplant Biotechnologies' management team and ensure that shareholders' interests are well served. Collplant Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Collplant Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oren Fahimipoor, Vice Operations | ||
| Michal Roytman, VP Marketing | ||
| Pr Shoseyov, Founder Scientist | ||
| Eran CPA, Deputy CFO | ||
| Elana Gazal, Vice Development | ||
| Ilana Belzer, Vice President - Operations | ||
| Yehiel Tal, CEO Director | ||
| Hadas Horowitz, Vice Resources |
Collplant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Collplant Biotechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (17.69) % | ||||
| Current Valuation | 36.55 M | ||||
| Shares Outstanding | 11.45 M | ||||
| Shares Owned By Insiders | 10.10 % | ||||
| Shares Owned By Institutions | 12.23 % | ||||
| Number Of Shares Shorted | 12.07 K | ||||
| Price To Earning | 92.60 X | ||||
| Price To Book | 2.88 X |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Collplant Stock
Moving against Collplant Stock
| 0.88 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.86 | GILD | Gilead Sciences | PairCorr |
| 0.8 | BHC | Bausch Health Companies | PairCorr |
| 0.74 | GANX | Gain Therapeutics | PairCorr |
| 0.69 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.